Date: 2011-09-06
Type of information: R&D agreement
Compound: design, synthesis, hit validation, lead optimization, biochemical pharmacology and ADMET & PK profiling
Company: Chiesi Farmaceutici (Italy) NiKem Research (Italy)
Therapeutic area: Respiratory diseases - Inflammatory diseases - Allergic diseases
Type agreement: R&D
Action mechanism:
Disease: asthma, COPD
Details: Chiesi Farmaceutici and NiKem Research have extended their research collaboration within the respiratory therapeutic area. Since 2001 Chiesi and NiKem successfully collaborate on several pre-clinical research projects where NiKem provides design, synthesis, hit validation, lead optimization, biochemical pharmacology and ADMET & PK profiling within different therapeutic areas on a fee-for-service basis. The current extension involves the period 2011-2014 through a multimillion multi-FTE-based service agreement on pre-clinical projects of interest for Chiesi in the respiratory therapeutic area and, in particular, focused on pathologies such as asthma and COPD.
Financial terms:
Latest news:
